SWOG 80702: Impressions on the Efficacy Data
April 21st 2025Panelists discuss how the efficacy data from SWOG 80702 demonstrated that shortened duration of adjuvant chemotherapy (3 months vs 6 months) yielded comparable survival outcomes while significantly reducing treatment-related toxicities, challenging previous standard-of-care approaches for patients with stage III colon cancer.
SWOG 80702: Overview of Study Design, Efficacy End Points, and Patient Characteristics
April 21st 2025Panelists discuss how SWOG 80702, a large-scale randomized clinical trial, employed a robust factorial design with clearly defined efficacy end points, including disease-free and overall survival, while enrolling a diverse patient population with stage III colon cancer to evaluate optimal adjuvant therapy duration and the impact of celecoxib.
Role of MRD Status in Treatment Intensification or De-Escalation of Adjuvant Therapy
April 14th 2025Panelists discuss how minimal residual disease (MRD) status, as detected through circulating tumor DNA analysis, can guide personalized treatment decisions by identifying patients who may benefit from intensification of adjuvant therapy and those who could safely undergo de-escalation of treatment regimens.
BESPOKE: ctDNA Clearance During and After ACT
April 14th 2025Panelists discuss how circulating tumor DNA (ctDNA) clearance rates during and after adjuvant chemotherapy (ACT) in the BESPOKE trial provide critical insights into treatment efficacy and may serve as an early predictor of long-term patient outcomes.
BESPOKE: Highlighting the Disease-Free Survival by ctDNA Status
April 7th 2025Panelists discuss how BESPOKE trial results demonstrate significantly improved disease-free survival rates in patients with negative circulating tumor DNA (ctDNA) status compared with those with detectable ctDNA, underscoring its potential as a powerful prognostic biomarker.
Overview of BESPOKE Patient Characteristics
April 7th 2025Panelists discuss how the BESPOKE trial enrolled a diverse cohort of patients with varying demographic profiles, disease stages, comorbidities, and treatment histories to ensure comprehensive representation for personalized medicine approaches.
CLM in GALAXY: MRD Predicts Adjuvant Therapy Benefit and Prognosis
November 12th 2024Panelists discuss how minimal residual disease (MRD) detection in patients with colorectal liver metastases (CLM) in the GALAXY study predicts both the benefit of adjuvant therapy and overall prognosis, potentially guiding more personalized treatment decisions.
GALAXY 24-Month Data from ESMO 2024: MRD Status and ctDNA Clearance Key in CRC
November 12th 2024Panelists discuss how the 24-month data from the GALAXY study presented at the European Society for Medical Oncology (ESMO) 2024 meeting underscore the importance of minimal residual disease (MRD) status and circulating tumor DNA (ctDNA) clearance as key prognostic and predictive factors in colorectal cancer (CRC) management.
Treatment Strategies in ctDNA-Positive CRC
November 12th 2024Panelists discuss how treatment strategies for circulating tumor DNA (ctDNA)–positive colorectal cancer (CRC) are evolving, with a focus on tailoring interventions based on molecular findings to improve patient outcomes and minimize unnecessary therapies.
GALAXY Study Results: ctDNA Status Predicts Outcomes and Treatment Benefit in CRC
November 5th 2024Panelists discuss how results from the GALAXY study reveal that circulating tumor DNA (ctDNA) status is a powerful predictor of outcomes and treatment benefit in patients with colorectal cancer (CRC), potentially revolutionizing personalized treatment approaches.
GALAXY Study: ctDNA-Based MRD Monitoring in Resected CRC
November 5th 2024Panelists discuss how the GALAXY study data demonstrate the effectiveness of circulating tumor DNA (ctDNA)–based minimal residual disease (MRD) monitoring in patients with resected colorectal cancer (CRC), potentially improving postsurgical care and outcomes.
ctDNA Insights From INTERCEPT, BESPOKE, COSMOS-CRC-01, and GALAXY Studies
October 29th 2024Panelists discuss how insights from the INTERCEPT, BESPOKE, COSMOS-CRC-01, and GALAXY studies are advancing our understanding of circulating tumor DNA’s (ctDNA) utility in colorectal cancer management, from early detection to treatment monitoring.
DYNAMIC: ctDNA-Guided Therapy on Adjuvant Chemotherapy Decisions in Stage II Colon Cancer
October 29th 2024Panelists discuss how the DYNAMIC trial data demonstrate the potential of circulating tumor DNA (ctDNA)–guided therapy to inform and optimize adjuvant chemotherapy decisions in patients with stage II colon cancer.
MRD Testing in CRC: Optimizing Chemo-Sparing Strategies and Residual Disease Control
October 22nd 2024Panelists discuss how minimal residual disease (MRD) testing in colorectal cancer (CRC) is facilitating the development of chemo-sparing strategies while maintaining effective control of residual disease.
ctDNA in CRC Management: Evolving Approaches for Personalized Care
October 16th 2024Panelists discuss how circulating tumor DNA (ctDNA) is revolutionizing colorectal cancer (CRC) management by enabling more personalized and precise approaches to diagnosis, treatment selection, and monitoring of disease progression.
Colorectal Cancer: Rising Prevalence and the Promise of ctDNA
October 16th 2024Panelists discuss how colorectal cancer rates are increasing, particularly among younger adults, while highlighting the potential of circulating tumor DNA (ctDNA) technology to improve early detection and treatment monitoring.
Introduction and CIRCULATE-Japan Overview
May 5th 2022Stacey A. Cohen, MD, and Mark Lewis, MD, introduce the 2022 ASCO GI abstract, “Association of Circulating Tumor DNA Dynamics With Clinical Outcomes in the Adjuvant Setting for Patients With Colorectal Cancer From an Observational GALAXY Study in CIRCULATE-Japan.”